Navigation Links
Liver disease: Understanding it will enable the provision of better treatment

In this prospective study, led by Dr Richard Moreau, INSERM Research Director (Mixed Research Unit 773 "Centre de Recherche biomdicale Bichat-Beaujon"; INSERM/Universit Paris Diderot) who is also a practitioner attached to the Hepatology Department of the Beaujon Hospital (AP-HP), researchers studied a cohort of 1343 patients from 12 European countries.

The results, published in the learned journal Gastroenterology, describe, for the first time, the specific profile of sufferers from this syndrome that is associated with cirrhosis. This also makes it possible to more clearly define the actual rules of attribution of the organs in those most severely affected, for whom there is a high risk of early death.

Cirrhosis is an irreversible liver disease. It is characterised by chronic inflammation that destroys the liver cells and produces anarchic regeneration in the form of nodules. The disease causes the liver to lose function and is accompanied by multiple complications. When these complications manifest (bleeding in the digestive tract, bacterial infection, accumulation of liquid in the abdomen, etc.), this is known as decompensated cirrhosis and the patients are hospitalised.

A certain number of these patients quickly develop a syndrome characterised by acute liver failure and/or failure of other vital organs1 (ACLF acute-on-chronic liver failure). The syndrome is associated with a high risk of death at one month and no diagnostic criteria were clearly established hitherto that might make it possible to describe the condition.

Through a consortium , the researchers in Mixed Research Unit 773 "Centre de Recherche biomdicale Bichat-Beaujon" (INSERM/Universit Paris Diderot), analysed data from 1343 patients hospitalised due to acute cirrhosis complications between February and September 2011 in 29 Hepatology Departments in 12

European countries . This enabled them to define robust diagnostic criteria for ACLF, indicating that one-third of the patients enrolled in the study had developed this syndrome.

The researchers noted that, compared to patients not suffering from ACLF, those who developed acute failure of an organ or organs were younger, were most frequently prey to alcoholism, suffered from a larger number of bacterial infections and had higher levels of white blood cells, as well as other markers of organ inflammation.

Quite unexpectedly, failure was most severe in patients without a previous history of cirrhosis complications. A high number of organ malfunctions (liver, kidneys, brain) were observed in these patients, including white blood cells in the blood and a mortality rate within one month of admission to hospital that was15 times greater than in patients who had a previous history.

"The identification of the criteria to define acute failure of an organ or organs enabled us to show that this is a separate syndrome from cirrhosis complications. In addition to organ failure and the high associated mortality, the development of the disease depends on the patient's age and medical history", explains Richard Moreau, INSERM Director of Research, and the Principal Investigator for the study. "We hope to be able to better identify those at risk of early death in order to improve their treatment. Furthermore, these results could lead to improving the current rules for assigning organs for grafting in the severest cases", he concludes.


Contact: Richard Moreau
INSERM (Institut national de la sant et de la recherche mdicale)

Related medicine news :

1. New ablation technique holds promise for liver cancer patients
2. April is IBS Awareness Month with Digestive & Liver Disease Center of San Antonio
3. Scarring May Raise Death Risk From Fatty Liver Disease
4. Polymer platform technology innovates drug delivery
5. ReviMedia Partners with RingRevenue to Deliver a Comprehensive Lead Generation Solution
6. The Signature Group, Inc. Partners with Alert Logic to Deliver Security and Compliance Solutions
7. SierraCRM Delivers Major Enhancements to the Process Manager Workflow Module for Sugar.
8. Fatty Liver Treatment
9. How “Fatty Liver Diet Guide” Helps People Treat Fatty Liver Quickly –
10. Liver transplantation for patients with genetic liver conditions has high survival rate
11. Incarceration, marijuana use and suicide attempts may hinder liver transplant eligibility
Post Your Comments:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/28/2015)... ... ... Pixel Film Studios is back again with ProPanel: Pulse . With ... Users have full control over angle of view, speed method, start point, end point, ... get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, all ...
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... recent 2015 American Dental Association meeting in Washington D.C. revolved around the fact that ... patient’s overall health. The talk stressed the link between periodontal disease (more commonly referred ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... changing the way that they are handling security in light of the recent terrorist ... presence in an attempt to stop an attack from reaching U.S. soil. Especially around ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology: